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Abstract
Background—Two-dose varicella vaccination has been available in Beijing since 2012 in the 
private sector. We investigated a varicella outbreak in a highly vaccinated elementary school 
population.
Methods—A cohort study was carried out and a varicella case was defined as an acute onset of 
generalized maculopapulovesicular rash without other apparent cause in a student attending the 
school from March 29 through May 17, 2015. Breakthrough varicella was defined as varicella >42 
days after the last vaccine dose among both 1- or 2-dose varicella vaccine recipients. Vaccination 
information was collected from immunization records; information on prior varicella and clinical 
presentations was collected by surveying students’ parents.
Results—Of the 1056 students in the school, 1027 (97.3%) reported no history of varicella. Prior 
to the outbreak, 98.6% of students had received ≥1 dose of varicella vaccine, and most (63.2%) 
students received two doses. Twenty varicella cases were identified for an overall attack rate of 
2.0%. Half of the cases occurred in the classroom of the index case-patient, a two-dose recipient 
who was not isolated after symptom onset. Breakthrough varicella accounted for 95% of cases 
(19/20) with attack rates of 14.3% (1/7), 1.6% (6/362) and 2.0% (13/649) among unvaccinated, 
one-dose, and two-dose students, respectively. Most case-patients (18/20, 90%) had <50 lesions. 
No difference in clinical presentations was found between one-dose and two-dose recipients with 
breakthrough varicella.
Conclusion—Moderate two-dose varicella vaccine coverage was insufficient to prevent a 
varicella outbreak. Two-dose recipients with breakthrough varicella are contagious. High two-dose 
varicella vaccine coverage and timely isolation of cases may be needed for varicella outbreak 
prevention in the two-dose era.
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1. Introduction
Varicella (chickenpox) is a highly contagious disease caused by infection with varicella 
zoster virus (VZV), and is characterized by a generalized pruritic vesicular rash. Although 
varicella is usually self-limiting and resolves within a week, severe complications (including 
death) can occur [1]. In the absence of vaccination, varicella is a universal infection acquired 
mainly in childhood. Varicella vaccines based on the live attenuated VZV (Oka strain) are 
now widely available throughout the world and represent the most effective measure for 
prevention and control of varicella [2,3].
In China, varicella vaccine was first licensed in 1998 for use as a single dose in the private 
sector for children aged at least 12 months of age. Uptake of the vaccine varies substantially 
among children in different geographic regions, ranging from low coverage in resource-
limited areas to high coverage in large cities, such as Beijing, the site of current study [4–7]. 
Single-dose vaccination has been provided free of charge by the Beijing government since 
2006 to unvaccinated students during outbreaks in school settings. However, varicella 
outbreaks still occur in school populations with high levels of one-dose coverage [5]. Since 
November 2012, a routine second dose of varicella vaccine has been offered in the private 
sector in Beijing to augment outbreak control; the municipality continues to offer free-of-
charge single-dose vaccinations for unvaccinated students during outbreaks in school 
setings. In Beijing the school system is predominantly public and consists of elementary 
schools (up to grade 6), middle schools (grades 7 through 9) and high schools (grades 10 
through 12).
On April 13, 2015, the Beijing Center for Disease Control and Prevention (CDC) was 
notified of a varicella outbreak in an elementary school. Because almost all students in the 
school had received either one or two doses of varicella vaccine before the outbreak, most 
cases were among vaccinated students and the majority were two-dose recipients. Beijing 
CDC and Xicheng District CDC investigated this outbreak to describe the outbreak; 
characterize clinical manifestations, particularly among two-dose recipients; assess vaccine 
effectiveness (VE); and examine risk factors associated with vaccinated cases and viral 
spread. This article summarizes findings from this investigation and discusses the 
implications for varicella outbreak control and vaccination policy in Beijing, China.
2. Methods
2.1. Outbreak setting
The outbreak occurred in a public elementary school for Grades 3 through 6 (“School A”) in 
Beijing. During the outbreak, 1056 students attended School A. The two five-story school 
buildings (north and south) included 28 classrooms—8 each for third and fourth grades, and 
6 each for fifth and sixth grades—with 1–6 classrooms on each floor. All sixth-grade classes 
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were located in the North building, while all other classes were located in the South 
building. Mixing of students occurred in the classrooms, hallways, play areas, school buses, 
and at afterschool activities.
2.2. Case definition, data and specimen collection
A case of varicella was defined as acute onset of generalized maculopapulovesicular rash 
without other apparent cause [8] that occurred between March 29 and May 17, 2015 in a 
student attending School A. Varicella among vaccinated students (breakthrough varicella) 
was defined as a varicella-like rash that developed >42 days after the latest vaccination 
before outbreak among both 1- or 2-dose varicella vaccine recipients [8]. We used reports 
from the school nurses and the infectious disease surveillance system of Beijing CDC to 
identify cases. Varicella became a notifiable disease in Beijing in late 2006. Parents of all 
students attending School A received and returned a questionnaire to provide information on 
history of prior varicella; for students with disease during the outbreak, information on 
disease severity, complications, and potential sources of exposure was collected by phone 
interview with the parents. Rash severity was categorized as mild (<50 lesions), moderate 
(50–499 lesions), or severe (≥500 lesions). The vaccination status of each student prior to the 
outbreak was obtained from immunization records. Lesion or scab specimens for laboratory 
confirmation were collected from case-patients after consent from the parents/guardians; 
detection of VZV DNA was performed with real-time polymerase chain reaction targeting 
the highly conserved ORF62 region according to manufacturer’s instructions (Uninovo, 
Jiangsu Province, China).
2.3. Outbreak control measures
Students with varicella were excluded from school until lesions crusted or no new lesions 
appeared (if their rash was solely maculopapular with no vesicles) once the outbreak was 
reported to Beijing CDC. From April 17 to 22, 2016, single-dose varicella vaccination was 
provided free of charge to unvaccinated students without a history of varicella. Afterschool 
activities were suspended and the classrooms, indoor play area, and school buses were 
disinfected after the outbreak was detected.
2.4. Statistical analyses
Sociodemographic factors and vaccination status of cases vs. non-cases were compared and 
tested with Pearson’s chi-squared test, Fisher’s exact test, or Student’s t-test, as appropriate. 
Vaccination coverage at the start of the outbreak was calculated as the proportion of 
vaccinated students among those without a history of varicella [9]. Those with prior history 
of varicella were excluded because they had developed immunity against varicella following 
natural infection and were not eligible for vaccination. Varicella VE was calculated using the 
equation: (1-attack rate among students who received 1- or 2-doses of vaccine/attack rate 
among unvaccinated students without a history of varicella)×100%. Because few students 
were unvaccinated and only one unvaccinated student was infected, we used historical attack 
rates among unvaccinated children in a child care center in the United States (US) [10] to 
calculate 1- and 2- dose VE, respectively. We evaluated potential risk factors for 
breakthrough disease among two-dose varicella vaccine recipients; specifically, age at 
receipt of second-dose vaccine, time since the latest vaccination before outbreak, and 
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interval between first- and second-dose vaccination. Severity of breakthrough varicella 
between one- and two-dose recipients was compared using rash severity, rash duration, 
fever, and duration of isolation. All data were analyzed by using SAS V9.3 (SAS Institute, 
Cary, NC).
3. Results
3.1. Study population
Among the 1056 students in School A, the 29 who had a history of varicella prior to the 
outbreak were excluded from analysis (Fig. 1). No staff or faculty developed varicella during 
the outbreak; all analyses were thus restricted to students. Among the 1027 students with no 
varicella history before the outbreak, 14 (1.3%) were unvaccinated, 364 (35.4%) had 
received one dose of vaccine, and 649 (63.2%) had received two doses of vaccine, totaling 
98.6% schoolwide vaccination coverage with ≥ 1 dose before the outbreak. There was no 
difference across grades in overall vaccination coverage (P = 0.80), but two-dose vaccination 
coverage was higher in the lower grades (69.9%, 63.6%, 62.2%, and 53.4% for grades 3, 4, 
5, and 6, respectively; P < 0.001 for trend). During the outbreak, seven unvaccinated 
students and two one-dose recipients received an additional dose of vaccine and were 
excluded from further analysis.
The average age of the 1018 students included in the study was 10.4 years (standard 
deviation [SD] = 10.3) and 49.6% were male. Among one-dose vaccine recipients (n = 362), 
the average age at vaccination was 27.3 months (SD = 24.4) and the average time since 
vaccination (prior to the outbreak) was 8.3 years (SD = 2.3). Among two-dose vaccine 
recipients (n = 649), the average ages at the first and second dose were 19.3 months (SD = 
8.4) and 8.3 years (SD = 1.2), respectively, and the average time since last vaccination 
before the outbreak was 1.9 years (SD = 0.1), with an average 6.7-year interval (SD = 1.3) 
between the first and second vaccine doses.
3.2. Outbreak
The outbreak lasted approximately 1.5 months, from March 29 through May 17, 2015. 
Among the 1018 students included in the study, a total of 20 cases were identified for an 
overall attack rate of 2.0%. Laboratory testing was performed for seven cases; all were 
among one-dose recipients and confirmed as VZV by PCR. The index case-patient had 
received two doses of varicella vaccine, was in the sixth grade, developed fever on March 28 
and moderate rash on March 29, and attended class without any isolation. Half of the cases 
occurred in the classroom of the index case-patient, of which 8 cases occurred within one 
incubation period (range 14–17 days) following rash onset of the index case-patient with 
school being the only known exposure per parental recall. All case-patients, excluding the 
index case-patient, were isolated with a median of 14 days (range: 6–21 days) after rash 
onset. There was no difference in attack rates between one- and two-dose vaccine recipients 
(1.6% vs. 2.0%, P = 0.70), but the attack rate among vaccinated students was lower than the 
attack rate among unvaccinated students (14.3%, P = 0.02) (Fig. 1). Using historical attack 
rates for varicella (88%) among unvaccinated children in a children care center [10], we 
calculated 1-dose varicella VE of 98.1% (95% confidence interval [CI]: 96.6–99.6%) and 2-
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dose VE of 97.7% (95% CI: 96.5–98.9%) for preventing any varicella. As no severe 
varicella was identified in this outbreak, the VE against severe disease was 100% for both 1- 
and 2- dose recipients.
The outbreak was restricted to 7 out of the 28 classes in School A: two classrooms in each of 
the fourth, fifth, and sixth grades, and one in the third grade. The overall attack rate in these 
7 classes was 9%, though the rate varied among unvaccinated (50%, 1/2), one-dose (7.2%, 
6/83), and two-dose students (8.4%, 13/155). The highest attack rate (29.4%) occurred in the 
index case-patient’s classroom; all other classrooms had attack rates lower than 10% (range: 
2.6–7.3%), with 1–3 cases per class. Only one peak of cases (n = 13) was observed in this 
outbreak, from April 12–16 (Fig. 2), and there was no difference in the vaccination coverage 
among students from the class of the index case and from other classes (P = 0.72).
3.3. Disease characteristics
Most case-patients had mild rash (18; 90%) and were vaccinated (19; 95%) and 5 (25%) had 
fever. There were no case-patients with severe rash. Only two case-patients had moderate 
rash. One was unvaccinated and the other was a two-dose vaccine recipient (the index case-
patient). No case-patients developed complications or were hospitalized. School exposure 
was the only source of infection for all case-patients, except two with unknown exposure 
history, including the index case-patient. The average age was 11.3 years (SD = 1.4) among 
case-patients and most were students in the sixth grade (11; 55%) (Table 1). Cases and non-
cases did not differ by vaccination status (P = 0.13), sex (P = 0.63), age at the second dose of 
vaccination (P = 0.33), or time since the last vaccine dose (P = 0.84), but cases were more 
likely than non-cases to be in sixth grade (55% vs. 19.4%, P = 0.005) (Table 1).
3.4. Disease severity and risk factors for two-dose breakthrough varicella
There were no differences between one- and two-dose recipients with breakthrough varicella 
in rash severity (P = 1.0), fever (P = 1.0), duration of rash (P = 1.0), or duration of isolation 
(P = 1.0) (Table 2). In two-dose vaccine recipients, age at the second dose (<8 vs. ≥8 years) 
and interval between first and second (≤5 vs. >5 years) doses were not associated with 
breakthrough varicella (P = 0.33 and 1.0, respectively) (Table 1).
4. Discussion
We investigated a varicella outbreak in a Beijing elementary school where vaccine coverage 
with ≥1 dose before the outbreak was nearly 100%, and where 2/3 of vaccinated students 
had received two doses of varicella vaccine. We found that disease was introduced by a two-
dose breakthrough case in a student and occurred almost exclusively among vaccinated 
students exposed at school. The majority of cases were among two-dose recipients, and half 
occurred in the class of the index case-patient who was not isolated after symptom onset. 
This study is the first report on a varicella outbreak initiated by a two-dose vaccine recipient 
with breakthrough varicella, indicating two-dose breakthrough varicella is still contagious. 
The findings further confirmed that children vaccinated with two doses of varicella vaccine 
may contract varicella, and moderate two-dose varicella vaccination coverage may not 
provide sufficiently high population immunity to prevent outbreaks [11]. This study also 
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confirms previous reports that one- and two-dose varicella vaccination is highly effective at 
mitigating the severity of breakthrough disease and reducing attack rates [12–14].
As varicella vaccine is well-accepted and one-dose coverage was high in school settings in 
Beijing [4], Beijing initiated a two-dose varicella vaccination schedule in 2012 to further 
reduce outbreaks in school settings with high one-dose vaccination coverage [5]. Compared 
with a previously reported varicella outbreak in a Beijing elementary school of similar size 
and ≥1 dose vaccination coverage (98%), but with very low two-dose coverage (0.2%) [5], 
the current outbreak—which occurred in a school with moderate two-dose varicella 
vaccination coverage—had a substantially shorter duration (27 vs. 121 days), as well as 
smaller size (20 vs. 87 cases) and lower attack rates (2.0% vs. 9.4%) [5]. Moreover, the 
current outbreak also had substantially lower attack rate and shorter duration than an 
outbreak in a similarly highly vaccinated elementary school (97%) but lower 2-dose 
coverage (39%) in the US which lasted 108 days with 9.5% attack rate [11]. These findings 
suggest that even moderate two-dose vaccine coverage is effective in controlling varicella 
outbreaks, but it is still not high enough to prevent varicella transmission and outbreaks. 
Further efforts to increase and maintain two-dose vaccine coverage rates as high as 80% or 
above, as the World Health Organization recommends [15], might help prevent occurrence 
of outbreaks or further reduce duration and size if they occur.
Clinical trial and several observational studies found increased varicella VE of 2-dose than 
1-dose vaccination [12–14,16]. Our outbreak investigation and another one in the similar 
school setting in US [11] found no difference in 1- and 2-dose varicella VE. The differential 
exposure to VZV in these two outbreaks, which was indicated in the low attack rates and 
substantial variation between classes, might lead to biased estimates on varicella VE, as 
equal exposure to disease is important but may not be achievable for VE assessment in 
outbreak investigations [17]. The findings of reduced outbreak size and duration in the 
current outbreak compared with outbreaks in similar school populations with high 1-dose 
coverage but almost no 2-dose vaccinees or low 2 dose coverage [5,11] were consistent with 
the changes in varicella outbreak characteristics before and after introduction of the 2-dose 
universal recommendation in the US [18], and the trend for smaller size of outbreaks with a 
greater proportion of 2-dose vaccine recipients [19]. Additionally, in the US a substantial 
decline of varicella disease burden had been observed after 2-dose varicella vaccination 
program introduction [20]. Taken together, these findings support that two doses of varicella 
vaccination offer increased protection than 1-dose vaccination and further increases in 2-
dose vaccination coverage may confer more preventive effect. Future analyses of 
surveillance data on reported varicella in Beijing before and after the two-dose 
recommendation will document whether similar changes occur in Beijing.
It is well documented that one-dose breakthrough varicella is contagious; even persons who 
present with only maculopapular rash may transmit infection to susceptible individuals [21], 
and can cause outbreaks in school and daycare settings [5,9,22–25]. However, outbreaks 
started by a two-dose breakthrough varicella have not been previously documented. 
Consistent with recent reports [12,13], the clinical presentation of two-dose breakthrough 
varicella in the current outbreak was generally mild, similar to one-dose breakthrough 
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varicella [14]. This outbreak investigation reveals that breakthrough varicella in two-dose 
recipients are still contagious.
Isolation of students with varicella had been recommended to prevent transmission in school 
settings [25]. Our outbreak investigation suggested that the lack of isolation of the index 
case-patient may have been the main factor contributing to this outbreak, as half of the cases 
occurred in the classroom of the index case-patient. This further emphasizes the importance 
for timely isolation in preventing outbreaks in two-dose era, even though cases of 
breakthrough varicella are likely less contagious than unvaccinated cases [21]. Moreover, 
this also serves as a reminder not to rely solely on two-dose vaccination to prevent and 
control varicella outbreaks; traditional measures for outbreak control are still important in 
two-dose era. However, it may be more challenging to carry out isolation of breakthrough 
cases in the two-dose vaccine era: they tend to have milder disease than unvaccinated 
varicella which may not be immediately diagnosed [12,14], and parents may be less 
motivated to keep their children from school for a perceived minor illness, particularly when 
doing so may cause economic or logistic hardship. The occurrence of this outbreak further 
indicates the necessity of enforcing isolation in school settings and improving education of 
parents to gain cooperation.
Our study has several limitations. The majority of cases were clinically diagnosed with only 
few being confirmed by laboratory testing. The numbers of unvaccinated students and cases 
were very small and we used historical attack rate among unvaccinated to calculate VE. On 
the other hand, we had very high students’ participation and vaccination information was 
collected from immunization records, therefore, limiting potential biases.
Our outbreak investigation demonstrated that two-dose breakthrough varicella can be 
contagious and moderate two-dose varicella vaccine coverage was insufficient to prevent a 
varicella outbreak. Therefore, increasing two-dose varicella vaccine coverage and enforcing 
timely isolation of varicella cases may be needed to further prevent and control varicella 
outbreaks in the two-dose varicella vaccination era. Universal 2-dose recommendation or 
free 2-dose vaccination during outbreak might be possible measures to further increase 2-
dose varicella vaccination coverage in Beijing, China.
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Fig. 1. 
Varicella vaccination, disease history, and case status among students in a varicella outbreak 
in School A, Beijing, 2015.
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Fig. 2. 
Varicella cases by date of rash onset and vaccination status (n = 20), School A, Beijing, 
March 29–May 17, 2015.
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Table 1
Comparison of students with and without varicella during a varicella outbreak, School A, Beijing, 2015 (N = 
1018).
Characteristic Students with
varicella (N = 20),
n (%)
Students without
varicella (N = 998),
n (%)
P value
Sex: female 9 (45.0) 504 (50.5) 0.63
Age in years prior to outbreak: mean (SD) 11.3 (1.4) 10.3 (1.2) <0.001
Vaccination status before outbreak 0.06
  Unvaccinated 1 (5.0) 6 (0.6)
  1-dose 6 (30.0) 356 (35.7)
  2-dose 13 (65.0) 636 (63.7)
Distribution of cases and non-cases across grades 0.005
  3 3 (15.0) 314 (31.5)
  4 4 (20.0) 294 (29.5)
  5 2 (10.0) 196 (19.6)
  6 11 (55.0) 194 (19.4)
Age at the second dose of varicella vaccination† 0.33
  <8 years 4 (30.8) 282 (44.3)
  ≥8 years 9 (69.2) 354 (55.7)
Interval between 1- and 2-dose vaccination* 1.0
  ≤5 years 0 (0.0) 43 (6.8)
  >5 years 13 (100.0) 593 (93.2)
*2-dose recipients only.
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Table 2
Disease severity between 1- and 2-dose breakthrough varicella case-patients during a varicella outbreak, 
School A, Beijing, 2015.
Characteristics of breakthrough
varicella
1-dose (N = 6),
n (%)
2-dose
(N = 13), n (%)
P
value
Rash severity 1.0
  Mild (<50 lesions) 6 (100.0) 12 (92.3)
  Moderate (50–499 lesions) 0 (0.0) 1 (7.7)
  Severe (≥500 lesions) 0 (0.0) 0 (0.0)
Most lesions were vesicular from parental recall 0.32
  Yes 1 (16.7) 0 (0.0)
  No 5 (83.3) 13 (100.0)
Rash duration 1.0
  <1 week 3 (50.0) 5 (38.5)
  ≥1 week 3 (50.0) 8 (61.5)
Fever 1.0
  Yes 1 (16.7) 4 (30.8)
  No 5 (83.3) 9 (69.2)
Duration of isolation 1.0
  ≤10 days 1 (16.7) 3 (25.0)
  >10 days 5 (83.3) 9 (75.0)
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